Trubion Pharmaceuticals (NASDAQ: [[ticker:TRBN]]), said today it has started a clinical trial of a drug for lupus, an autoimmune disease. The drug, SBI-087, is made to hit a target called CD20, that’s currently blocked by Genentech and Biogen Idec’s rituximab (Rituxan) for patients with a different form of autoimmune disease, rheumatoid arthritis. The Trubion drug-which is also being tested for rheumatoid arthritis—is being developed in partnership with Madison, NJ-based Wyeth.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
